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S ystemic sclerosis (scleroderma) is an autoimmunedisorder of unclear etiology that leads to ﬁbrosis
and vascular injury of the skin and multiple organs,
including the lungs, heart, gastrointestinal tract, kid-
neys, and the musculoskeletal system. It is classiﬁed as
either diffuse or limited cutaneous based on the extent
of skin thickening. In the diffuse form of systemic
sclerosis, skin thickening is extensive and usually oc-
curs within 1 year, compared with the limited cuta-
neous form, in which skin thickening is often conﬁned
to the face, ﬁngers, and hands. Diffuse systemic scle-
rosis is also characterized by Raynaud’s phenomenon
and signiﬁcant visceral involvement.
Renal complications are common in patients with
systemic sclerosis. The most serious renal manifestation
is scleroderma renal crisis, which occurs in up to 10%
of patients with diffuse cutaneous systemic sclerosis,
and only rarely (1%–2%) in limited cutaneous sys-
temic sclerosis.1,2 It is a relatively early complication of
systemic sclerosis, typically occurring within 5 years of
diagnosis, and may be the initial presentation of sys-
temic sclerosis.3 Scleroderma renal crisis is usually
characterized by abrupt onset of marked hypertension,
rapidly progressive renal failure due to thrombotic
microangiopathy (TMA), vasospasm, and tissue
ischemia. However, up to 10% of patients with
scleroderma renal crisis are normotensive, although
their blood pressure may be increased from baseline
values.4
CASE PRESENTATION
A 34-year-old man presented with a 2-week history of
progressively worsening shortness of breath and he-
moptysis. His past medical history dated back to 6
months prior when he presented to the hospital with
several weeks’ history of maculopapular rash on his
forearms and legs that was associated with arthralgia.International Reports (2016) 1, 311–315Because he had positive rapid plasma reagin, antinuclear
antibody, and Lyme titer, he was treated for presumed
secondary syphilis, and then subsequently for Lyme
disease. His symptoms progressed, so he was referred to
rheumatology.Hisworkup at that time revealed elevated
creatinine phosphokinase and transaminases levels,
positive anticyclic citrullinated peptide antibody,
antithreonyl-tRNAsynthetase, and antitopoisomerase I.
Other tests, such as antidouble-strandedDNA, anti-Smith,
ribonucleoprotein, anti-Sjögren’s-syndrome-related anti-
gen A, anti-Sjögren’s-syndrome-related antigen B, anti
Jo-1, antimitochondrial antibody, antismooth muscle
antibody, HIV, hepatitis B and C, Lyme titer, parvovirus,
chlamydia, and gonorrhea, were all negative.
Shortly after testing, he was hospitalized for pro-
gressive myalgia, arthralgia, and dysphagia associated
with severe right shoulder pain, a 50-lb unintentional
weight loss, and skin thickening in the hands. He was
treated with a short course of low-dose glucocorticoids.
Magnetic resonance imaging without contrast was
suggestive of myositis.
He had an outpatient muscle biopsy that showed
myositis; his creatinine phosphokinase level at the time
was about 3000 U/l. He was diagnosed with systemic
sclerosis based on his clinical symptoms, and positive
anti topoisomerase 1 and cyclic citrullinated peptide
antibody (>250.0 U). He was subsequently prescribed
prednisone 60 mg daily and methotrexate 12 mg
weekly. Routine lab tests performed at this time
showed hemoglobin of 14.0 g/dl, platelet count of
197/nl, and a serum creatinine level of 0.7 mg/dl. Spot
urine protein-creatinine ratio was 0.74 g/g. One week
after initiation of prednisone, his serum creatinine level
increased from 0.7 to 2.2 mg/dl.
He presented to the hospital 2 weeks later with pro-
gressivelyworsening shortness of breath, dysphagia, and
hemoptysis. At the time, hewas taking 40mg prednisone
daily, gabapentin 300 mg 3 times daily, folic acid 1 mg
daily, and acetaminophen-oxycodone as needed for pain.311
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pressure was 129/84 mm Hg and his pulse was 99 bpm.
Baseline blood pressure was about 100/60 mm Hg. His
physical exam was normal with the exception of mild
skin tightening of his hands and forearms, and diffuse
decreased breath sounds. He did not have any syno-
vitis, joint swelling, tendon rubs, or proximal weak-
ness on exam. See Table 1 for relevant laboratory test
results on admission. Peripheral smear revealed aniso-
cytosis, poikilocytosis, and many schistocytes.
Urine microscopy revealed dysmorphic red blood
cells and numerous granular casts. Urine drug screen
was negative. Echocardiography showed an ejection
fraction of 35%, with left ventricular moderate global
hypokinesis, mild mitral regurgitation, and aortic
valvular sclerosis. Chest radiograph showed equivocal
left lower lobe opacity.
He was started on broad-spectrum antibiotics with
vancomycin, cefepime, and azithromycin for suspected
pneumonia. Shortly after admission, he developed
worsening dyspnea and tachycardia, with an acute drop
in hemoglobin to 7 mg/dl. His serum creatinine level
continued to worsen, with associated anuria. He was
diagnosed with TMA; the differential diagnoses at this
time included scleroderma renal crisis, thrombotic
thrombocytopenia purpura, antiphospholipid antibody
syndrome, or atypical hemolytic uremic syndrome. He
was started on captopril 6.25 mg 3 times daily on Hospital
Day 1. The dose could not be titrated up because his
systolic blood pressure was in the range of 80 to 99
mm Hg. Plasma exchange was started on Hospital Day 1.
Hemoglobin level, platelet count, lactate dehydrogenase
and reticulocyte counts rapidly improved after 5 sessions
of plasma exchange. Hemodialysis was initiated on Hos-
pital Day 2 due to deteriorating kidney function, anuria,
and hyperkalemia. On Hospital Day 3, antineutrophil
cytoplasmic autoantibodies, antimyeloperioxidase andTable 1. Relevant laboratory results
Test Result Reference range
Hemoglobin (g/dl) 8.9 13.3–17.7
Platelets (/nl) 29 150–400
Haptoglobin (mg/dl) < 8 30–200
Creatinine (mg/dl) 6.2 0.7–1.3
Blood urea nitrogen (mg/dl) 116 8–22
Total bilirubin (mg/dl) 5.5 0.2–1.0
Indirect bilirubin (mg/dl) 1.8 0.0–0.3
Alanine transaminase (IU/l) 166 0–54 U/l
Alkaline phosphatase (IU/l) 70 50–135
Lactate dehydrogenase (IU/l) 10,461 310–620
Creatinine phosphokinase (IU/l) 2376 40–250
Complementsa Normal
Disseminated intravascular coagulation
panel
Negative
aC3, C4, and CH50.
312antiproteinase-3, antiglomerular basement membrane
antibodies, anticardiolipin assay (cardiolipin antibodies
IgG and IgM and b-2 glycoprotein-1), and ADAMTS-13
were reported to be normal.
A kidney biopsy was done on Hospital Day 7. It
showed TMA with predominant involvement of blood
vessels and secondary acute and severe ischemic
glomerular changes involving 17 out of 17 glomeruli
(Figures 1–6). Diffuse and severe tubular degenerative
changes and arteriosclerosis were noted. Immunoﬂuo-
rescence microscopy revealed no deposition of IgG, IgA,
IgM, C3, and C1q, providing evidence against immune
complex glomerular diseases. Light microscopy revealed
ﬁndings consistent with severe TMA with predominant
involvement of blood vessels and secondary ischemic
glomerular changes. The predominance of TMA
vascular changes on the biopsy in contrast to glomerular
involvement, and the clinical presentation pointed to a
diagnosis of scleroderma renal crisis.
The patient was discharged on enalapril 10 mg daily,
mycophenolate mofetil 1000 mg twice a day, and in-
structions for hemodialysis 3 times a week. He did well
until 4 weeks later, when he reported atrial ﬁbrillation
with rapid ventricular response. At this time, his serum
creatinine level was 3.25 mg/dl with a 24-hour creati-
nine clearance of 26 ml/min. Hemodialysis was dis-
continued. He was discharged home on Hospital Day 4
with furosemide and enalapril. He was rehospitalized
16 days later with shortness of breath and hypotension
(systolic blood pressure 70–89 mm Hg). His chest
radiograph was normal with no signs of pulmonary
edema. Clinically, he was euvolemic. His repeat echo-
cardiogram revealed a worsening ejection fraction of
10% from 35% 10 weeks prior. A cardiac catheteriza-
tion revealed low right-sided ﬁlling pressures with a
pulmonary wedge pressure of 9 mm Hg. Cardiac
index was 1.59. There was no evidence of signiﬁcantFigure 1. Mucoid intimal edema.
Kidney International Reports (2016) 1, 311–315
Figure 4. Fibrinoid necrosis in an arteriole.Figure 2. Intimal edema and ﬁbrin.
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was initiated. However, the patient went into cardiac
arrest and died on Hospital Day 6.
DISCUSSION
A diagnosis of scleroderma renal crisis was strongly
favored in this patient based on the ﬁnding of throm-
botic microangiopathy, the presence of preexisting
high suspicion of systemic sclerosis, and recent
glucocorticoid use.
Scleroderma renal crisis is associated strongly with a
positive speckled antinuclear antibody pattern as well as
with positive anti-RNA polymerase III. Because renal
crisis is more common in diffuse systemic sclerosis, it is
associated more with positive antitopoisomerase in
contrast to anticentromere, which is seen more with
limited cutaneous systemic sclerosis. The ﬁndings of
positive antithreonyl-tRNAsynthetase and anticyclic cit-
rullinated peptide antibody in this patient suggest an
overlap syndromewith other systemic rheumatic diseases.Figure 3. Fibrin thrombus in an arteriole.
Kidney International Reports (2016) 1, 311–315Scleroderma renal crisis in the absence of hyperten-
sion is associated with worse renal outcome and higher
mortality compared with scleroderma renal crisis with
hypertension.4 The poor prognosis has been attributed
to subclinical renal injury leading to TMA in the setting
of delayed diagnosis. This presentation is more common
in patients with cardiac involvement and previous
treatment with glucocorticoids, as in this patient.
Although this patient was normotensive, his blood
pressure of 125/84 mm Hg upon admission was higher
than his baseline blood pressure of 100/60 mm Hg.
The risk factors for developing scleroderma renal
crisis include the presence of diffuse disease; positive
antitopoisomerase III antibody test; onset of sclero-
derma within the previous 1 year; fatigue, weight loss,
and polyarthritis; drugs such as prednisone at doses
>15 mg/day, cyclosporine within the preceding 3
months, and cocaine use. Other risk factors reported
include contractures at the large joints, new-onset
anemia, new heart failure, or pericardial effusion.2Figure 5. Ischemic glomerulus.
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Figure 6. Diffuse tubular injury.
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clinical suspicion and presence of autoantibodies. The
presence of TMA on a renal biopsy does not provide a
deﬁnite diagnosis, but is useful for excluding other
diagnoses and predicting clinical outcome. TMA is
characterized by microangiopathic hemolytic anemia,
thrombocytopenia, elevated lactate dehydrogenase
levels, and low serum haptoglobin level. Micro-
angiopathic hemolytic anemia and thrombocytopenia
may be present in up to 60% and 50%, respectively, of
patients with scleroderma renal crisis.5 The urine
sediment is usually normal, but may be associated with
microscopic hematuria and proteinuria. Urinary gran-
ular casts may be present on urine microscopy.
The differential diagnoses for TMA are broad and
include malignant hypertension, thrombotic thrombo-
cytopenia purpura, atypical hemolytic uremic syn-
drome, radiation nephritis, antiphospholipid antibody
syndrome, chronic transplantation rejection, drug
toxicity due to antimicrobial agents, quinine, calcineurin
inhibitors, and chemotherapy drugs such as antivascular
endothelial growth factor agents and gemcitabine, to
name a few. Procoagulant states such as malignancy and
oral contraceptive use have also been shown to cause
TMA. The etiology of TMA in a large percentage of cases
remains unknown.5 In this patient, thrombotic throm-
bocytopenia purpura and antiphospholipid syndrome
were excluded because ADAMTS-13 and anticardiolipin
assay were normal. The other diagnoses were excluded
based on his history.
TMA is characterized histologically by vessel wall
thickening with endothelial swelling and detachment
of endothelial cells from the basement membrane and
formation of platelet-ﬁbrin hyaline microthrombi that
occlude arterioles and capillaries.5 These changes are
typically localized to the small arcuate and interlobular
arteries and the glomeruli. In contrast to atypical314hemolytic uremic syndrome and thrombotic thrombo-
cytopenia purpura, the renal biopsy ﬁndings in
scleroderma renal crisis, like malignant hypertension,
have a predominance of primary small vessel changes
compared with glomeruli alterations.6 The character-
istic ﬁnding in scleroderma renal crisis is intimal pro-
liferation and thickening that leads to narrowing and
obliteration of the vascular lumen, with concentric
onion-skin hypertrophy.
Acute vascular changes usually manifest as intimal
accumulation of mucoid material, thrombosis, and
ﬁbrinoid necrosis, as seen in Figures 1, 3, and 4. The
severity and extent of the acute vascular injury is
associated with poor prognosis.7 Chronic ﬁndings
usually manifest as onion-skin lesions and subse-
quently ﬁbrointimal sclerosis with adventitial
ﬁbrosis. Glomerular changes may occur as a result of
the vascular injury or decreased renal perfusion, and
may manifest as endothelial swelling, glomerular
capillary thrombosis, and ischemic glomerulus, which
is characterized by wrinkling and thickening of the
capillary walls and shrinkage of the glomerular tuft
(Figure 5). Tubulointerstitial changes may occur as a
result of the vascular injury, and typically manifest as
ischemic acute tubular necrosis (Figure 6), and sub-
sequently as tubular atrophy and interstitial ﬁbrosis.
Immunoﬂuorescence and electron microscopy are of
limited utility in the diagnosis of scleroderma renal
crisis. However, the presence of peritubular capillary
C4d deposits in scleroderma renal crisis, as well as
vascular thrombosis and severe glomerular ischemic
collapse, have been shown to correlate with poor renal
recovery.7
Angiotensin-converting enzyme inhibitors are the
ﬁrst-line treatment for both hypertensive and normo-
tensive scleroderma renal crisis. Since their introduc-
tion the late 1970s, patients’ 5-year survival has
increased from <10% to up to 65%.2 Although use of
angiotensin-converting enzyme inhibitors has been
associated with spontaneous regression of systemic
sclerosis skin manifestations in patients with positive
RNA polymerase III, they have not been shown to
cause skin regression.8,9
It is important to avoid sudden and excessive de-
creases in blood pressure because excessive reduction
in renal perfusion may lead to acute tubular necrosis.
Once the diagnosis of scleroderma renal crisis is made, a
low-dose angiotensin-converting enzyme inhibitor
should be continued indeﬁnitely. As in all other forms
of renal dysfunction, nephrotoxic drugs must be
avoided. Plasma exchange is considered only in cases
of severe TMA. Administration of eculizimab was
considered brieﬂy for this patient. However, because
the patient had rapid hematologic recovery afterKidney International Reports (2016) 1, 311–315
E Asamoah-Odei: Scleroderma Renal Crisis NEPHROLOGY ROUNDSplasma exchange therapy and initiation of captopril,
this was not pursued. Also, from our literature review,
we found no data to support the use of eculizimab in
scleroderma renal crisis.
As many as 25% of patients with scleroderma renal
crisis require dialysis at presentation. Long-term sur-
vival is poor, especially if there is no renal recovery.
The improvement in renal function with discontinua-
tion of hemodialysis within 6 weeks supports the
diagnosis of scleroderma renal crisis, and is consistent
with previously published beneﬁts of captopril use in
scleroderma renal crisis.CONCLUSION
Scleroderma renal crisis in the absence of hypertension
is associated with worse renal outcomes and increased
mortality. It should be suspected in any patient with
systemic sclerosis, especially in patients who have
diffuse cutaneous systemic sclerosis and have recently
been treated with glucocorticoids. Prompt initiation of
an angiotensin-converting enzyme inhibitor is of
utmost importance despite the presence of acute kidney
injury and normal blood pressures. Prompt treatment
may be associated with improved renal outcomes.
However, scleroderma renal crisis in the absence of
hypertension is associated with high mortality due to
associated cardiac disease.DISCLOSURES
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